Literature DB >> 26366891

Gender Differences in Long-Term Survival after Surgery for Non-Small Cell Lung Cancer.

Yukihiro Yoshida1, Tomonori Murayama1, Yasunori Sato2, Yoshio Suzuki3, Haruhisa Saito4, Yukihiro Nomura1.   

Abstract

Background This retrospective study examined gender differences in non-small cell lung cancer (NSCLC) by analyzing surgical cases at a single institution. Patients and Methods In this study, 735 NSCLC patients who underwent surgery from 1995 to 2010 were included. Clinical and pathological characteristics were retrieved by reviewing charts retrospectively, and variables between genders were compared. Results There were 489 males and 246 females in the study. The percentage of screening-detected lung cancers (83.7%), never smokers (82.9%), adenocarcinoma histology (90.7%), and pathological stage IA (42.7%) was higher in females than that in males (71.2, 8.2, 51.3, and 23.1%, respectively). Female patients had fewer cases of coronary artery disease (2.8%) and fewer pneumonectomy cases (2.0%) than the male patients (7.4 and 5.3%, respectively). The median follow-up period after surgery was 5.9 years. The overall survival rates at 5 years were 57.3% for males and 76.2% for females (p < 0.001, log-rank test). Based on univariate analysis, we report that histology, smoking history, and pathological stage were significant prognostic factors in addition to gender. Based on multivariate analysis, pathological stage III/IV (hazard ratio, 3.60; 95% confidence interval [CI], 2.84-4.54) and female gender (hazard ratio, 0.55; 95% CI, 0.37-0.82) were significant prognostic factors. Subgroup analysis demonstrated that female gender and adenocarcinoma histology were significant positive prognostic factors only in pathological stages I and II (n = 557). Conclusion Female gender as well as pathological stage was favorable prognostic factors. The survival advantage observed in female NSCLC patients was limited to those with cancer at stages I and II. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26366891     DOI: 10.1055/s-0035-1558995

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  4 in total

1.  Metastases with definitive pathological diagnosis but no detectable primary tumor: A surveillance epidemiology and end results-based study.

Authors:  Lianyuan Tao; Haibo Yu; Yadong Dong; Guanjing Tian; Zhiyuan Ren; Deyu Li
Journal:  Cancer Med       Date:  2019-08-13       Impact factor: 4.452

2.  RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T1-3N0-2 M0 non-small cell lung cancer.

Authors:  Yunkui Zhang; YaoChen Li; Rongsheng Zhang; Yujie Zhang; Haitao Ma
Journal:  BioData Min       Date:  2019-08-23       Impact factor: 2.522

3.  Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.

Authors:  Friedemann Schad; Anja Thronicke; Megan L Steele; Antje Merkle; Burkhard Matthes; Christian Grah; Harald Matthes
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.752

4.  NOTCH Single Nucleotide Polymorphisms in the Predisposition of Breast and Colorectal Cancers in Saudi Patients.

Authors:  Ibrahim O Alanazi; Jilani Purusottapatnam Shaik; Narasimha Reddy Parine; Abdulrahman Al Naeem; Nahla A Azzam; Majid A Almadi; Abdulrahman M Aljebreen; Othman Alharbi; Mohammad Saud Alanazi; Zahid Khan
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.